Esophageal Cancer in Relative Increases Barrett’s Risk
By LabMedica International staff writers Posted on 09 Nov 2017 |
Image: A histopathology of Barrett\'s esophagus, characterized by the presence of specialized columnar epithelium with goblet cells (Photo courtesy of Dr. John R Goldblum, MD).
Barrett's esophagus refers to an abnormal change (metaplasia) in the cells of the lower portion of the esophagus. It is characterized by the replacement of the normal stratified squamous epithelium lining of the esophagus by simple columnar epithelium with goblet cells.
While it is well known that esophageal adenocarcinoma is a common complication of Barrett’s esophagus, the significance of family history of esophageal adenocarcinoma in disease progression among patients with Barrett’s esophagus is not well-known. Patients with Barrett’s esophagus who have a first-degree relative with esophageal adenocarcinoma are at 5.5-fold increased risk for progression to esophageal adenocarcinoma.
Scientists at Thomas Jefferson University Hospital (Philadelphia, PA, USA) conducted a retrospective cohort study including 301 patients with Barrett’s esophagus undergoing radiofrequency ablation at a tertiary care center. The investigators pooled data from electronic medical records on patient age, sex, age at diagnosis of Barrett’s esophagus and esophageal adenocarcinoma, pathology and length of Barrett’s esophagus segment. They assessed information on family history in all patients, including those with and without esophageal adenocarcinoma.
The team excluded from the study 19 patients with intramucosal adenocarcinoma on index endoscopy. Overall, 6.7% of patients with Barrett’s esophagus had a first-degree relative with a history of esophageal adenocarcinoma. Of these, 21.1% had disease that progressed to esophageal adenocarcinoma compared with 8.7% of patients without a first-degree relative with esophageal adenocarcinoma. After adjusting for sex and the number of radiofrequency ablation treatments, they found that family history of esophageal adenocarcinoma was a significant independent predictor for progression to adenocarcinoma (OR=5.55; 95% CI, 1.47-20).
Christina J. Tofani, MD, a gastroenterologist and lead author of the study, said, “Our study suggests that family history of esophageal adenocarcinoma is an independent risk factor for the development of esophageal adenocarcinoma in Barrett’s esophagus patients and should be carefully considered in patient surveillance and radiofrequency ablation treatment, beyond current recommended guidelines.” The study was presented at the World Congress of Gastroenterology at American College of Gastroenterology Annual Scientific Meeting, held October 13-18, 2017, in Orlando, FL, USA.
Related Links:
Thomas Jefferson University Hospital
While it is well known that esophageal adenocarcinoma is a common complication of Barrett’s esophagus, the significance of family history of esophageal adenocarcinoma in disease progression among patients with Barrett’s esophagus is not well-known. Patients with Barrett’s esophagus who have a first-degree relative with esophageal adenocarcinoma are at 5.5-fold increased risk for progression to esophageal adenocarcinoma.
Scientists at Thomas Jefferson University Hospital (Philadelphia, PA, USA) conducted a retrospective cohort study including 301 patients with Barrett’s esophagus undergoing radiofrequency ablation at a tertiary care center. The investigators pooled data from electronic medical records on patient age, sex, age at diagnosis of Barrett’s esophagus and esophageal adenocarcinoma, pathology and length of Barrett’s esophagus segment. They assessed information on family history in all patients, including those with and without esophageal adenocarcinoma.
The team excluded from the study 19 patients with intramucosal adenocarcinoma on index endoscopy. Overall, 6.7% of patients with Barrett’s esophagus had a first-degree relative with a history of esophageal adenocarcinoma. Of these, 21.1% had disease that progressed to esophageal adenocarcinoma compared with 8.7% of patients without a first-degree relative with esophageal adenocarcinoma. After adjusting for sex and the number of radiofrequency ablation treatments, they found that family history of esophageal adenocarcinoma was a significant independent predictor for progression to adenocarcinoma (OR=5.55; 95% CI, 1.47-20).
Christina J. Tofani, MD, a gastroenterologist and lead author of the study, said, “Our study suggests that family history of esophageal adenocarcinoma is an independent risk factor for the development of esophageal adenocarcinoma in Barrett’s esophagus patients and should be carefully considered in patient surveillance and radiofrequency ablation treatment, beyond current recommended guidelines.” The study was presented at the World Congress of Gastroenterology at American College of Gastroenterology Annual Scientific Meeting, held October 13-18, 2017, in Orlando, FL, USA.
Related Links:
Thomas Jefferson University Hospital
Latest Pathology News
- AI-Powered Digital Imaging System to Revolutionize Cancer Diagnosis
- New Mycobacterium Tuberculosis Panel to Support Real-Time Surveillance and Combat Antimicrobial Resistance
- New Method Offers Sustainable Approach to Universal Metabolic Cancer Diagnosis
- Spatial Tissue Analysis Identifies Patterns Associated With Ovarian Cancer Relapse
- Unique Hand-Warming Technology Supports High-Quality Fingertip Blood Sample Collection
- Image-Based AI Shows Promise for Parasite Detection in Digitized Stool Samples
- Deep Learning Powered AI Algorithms Improve Skin Cancer Diagnostic Accuracy
- Microfluidic Device for Cancer Detection Precisely Separates Tumor Entities
- Virtual Skin Biopsy Determines Presence of Cancerous Cells
- AI Detects Viable Tumor Cells for Accurate Bone Cancer Prognoses Post Chemotherapy
- First Ever Technique Identifies Single Cancer Cells in Blood for Targeted Treatments
- Innovative Blood Collection Device Overcomes Common Obstacles Related to Phlebotomy
- Intra-Operative POC Device Distinguishes Between Benign and Malignant Ovarian Cysts within 15 Minutes
- Simple Skin Biopsy Test Detects Parkinson’s and Related Neurodegenerative Diseases
- Bioinformatics Tool to Identify Chromosomal Alterations in Tumor Cells Can Improve Cancer Diagnosis
- Coin-Sized Device Rapidly Isolates Blood Plasma for Quicker and More Precise Clinical Diagnoses